Nesfatin-1 and other hormone alterations in polycystic ovary syndrome

Deniz, Rulin; Gürateş, Bilgin; Aydın, Süleyman; Çelik, Hüsnü; Şahin, İ̇brahim; Baykuş, Yakup; Çatak, Zekiye; Aksoy, Aziz; Citil, Cihan; Güngör, Sami

doi:10.1007/s12020-012-9638-7

Cited by 58 publications

(48 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to that study, Deniz and cols. revealed a negative correlation between nesfatin-1 and BMI, fasting blood glucose, and HOMA-IR in patients with polycystic ovary syndrome, an endocrine disorder commonly presenting with obesity and insulin resistance as well as hyperandrogenemia and hirsutism (20). Ding and cols.…”

Section: Discussionmentioning

confidence: 98%

Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes

Ademoglu¹,

Gorar

Keskin

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods: Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results: Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion: Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area. Arch Endocrinol Metab. 2017;61(5):455-9

show abstract

Section: Discussionmentioning

confidence: 98%

Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes

Ademoglu¹,

Gorar

Keskin

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…Hypothalamic satiety peptides that are known to be effective on energy balance, obesity and glucose metabolism are also affecting gonadal functions, having both physiologic and pathologic regulatory roles on the ovaries [20]. Previously, low nesfatin-1 levels were found to be associated with delayed puberty in female rats and nesfatin-1 injection had dramatic effects on the levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) [16,21].…”

Section: Introductionmentioning

confidence: 99%

Nesfatin-1 levels and metabolic markers in polycystic ovary syndrome

Alp¹,

Görmüş²,

Güdücü

et al. 2015

Gynecological Endocrinology

View full text Add to dashboard Cite

Nesfatin-1 is a novel hormone synthesized in hypothalamus and several other specific organs to regulate eating habits, appetite and is thought to be related to ovarian functions. In our study, we aimed to evaluate the nesfatin-1 levels with other metabolic parameters in polycystic ovary syndrome (PCOS), a condition that is known to be related to both ovarian functions and obesity. Study subjects were chosen from the women attended to the Obstetrics and Gynecology Department of Istanbul Bilim University, Avrupa Florence Nightingale Hospital. Thirty-five healthy control subjects and 55 PCOS patients were included. Blood samples were obtained on the 3rd day of the menstrual cycle. Luteinizing hormone (LH), follicle stimulating hormone (FSH), free testosterone (FT), dehydroepiandrosterone sulfate (DHEA-S), insulin, fasting blood glucose (FBG), high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG), sex hormone binding globulin (SHBG) levels were measured; homeostatic model assessment-insulin resistance (HOMA-IR) value was calculated. The nesfatin-1 levels were measured by competitive inhibition ELISA method. Due to our results, PCOS patients were having lower nesfatin-1 levels compared to the control group and this was not seemed to be related to body mass index (BMI) levels. This is an important result to be investigated in larger study groups and is related to other metabolic markers.

show abstract

“…Li et al (21) stated that plasma nesfatin-1 levels were lower in adults with type 2 diabetes when compared to the healthy adults. Deniz et al (28) determined that serum nesfatin-1 levels were lower in 30 women with polycystic ovary syndrome who had insulin resistance compared to the control group. In our study, although statistically insignificant, fasting and postprandial serum nesfatin-1 levels in the insulin-resistant and MetS group were lower compared to the non-resistant group.…”

Section: Discussionmentioning

confidence: 99%

“…There is no study evaluating the fasting and postprandial nesfatin-1 levels in children with MetS. When we considered the studies that claimed to determine a correlation between nesfatin-1 and insulin resistance, we considered that, in particular, insulin resistance has a partial negative effect on nesfatin-1 increase in obese children (7,27,28). Furthermore, circulating concentrations of nesfatin-1 were not changed by an oral glucose load, in spite of a significant increase in insulin concentration in the blood.…”

Section: Discussionmentioning

confidence: 99%